Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD) will present a poster on its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026 in San Diego, April 17–22.

The poster covers preclinical work on a novel Kinesin target and the oral degrader BBI-940, which is in the ongoing first‑in‑human KOMODO‑1 trial (NCT07408089) for advanced ER+/HER2‑ and TNBC‑LAR breast cancers. Presentation: April 21, 2026, 2:00–5:00 PM PT, Poster Section 53, Board 18, Abstract LB361.

News Market Reaction – BOLD

+1.74%

+1.74% Session close to close

In the Mar 18 session, BOLD gained 1.74%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.

Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. Boundless is developing BBI-940, a potentially first-in-class, oral, selective, Kinesin degrader, which is the subject of the ongoing first-in-human KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology) clinical trial (NCT07408089) in patients with advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR).

Details of the presentation are as follows:

Title: Selective degradation of a novel kinesin as a potential therapeutic strategy addressing high-risk extrachromosomal DNA (ecDNA) positive cancers, including breast cancer
Abstract Presentation Number: LB361
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday, April 21, 2026, 2:00 PM - 5:00 PM PT
Location: Poster Section 53
Poster Board Number: 18

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class oral, selective, Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Contacts:
James Lee, Boundless Bio
jlee@boundlessbio.com

Investors
Renee Leck
renee@thrustsc.com

FAQ

When will Boundless Bio (BOLD) present the oral Kinesin degrader poster at AACR 2026?

Boundless Bio will present on April 21, 2026 during the AACR Annual Meeting. According to Boundless Bio, the poster session is scheduled 2:00–5:00 PM PT, Poster Section 53, Board 18 (Abstract LB361).

What is BBI-940 and which trial is testing it (BOLD)?

BBI-940 is an oral, selective Kinesin degrader in a first‑in‑human trial. According to Boundless Bio, KOMODO‑1 (NCT07408089) is enrolling patients with advanced ER+/HER2‑ and TNBC‑LAR breast cancers.

What will the AACR 2026 poster from Boundless Bio (BOLD) describe?

The poster will describe selective degradation of a novel Kinesin targeting ecDNA‑positive cancers. According to Boundless Bio, it highlights preclinical evidence and rationale for targeting ecDNA segregation in high‑risk breast cancers.

Where can investors view Boundless Bio's (BOLD) AACR poster during the meeting?

Investors can view the poster in person at Poster Section 53, Board 18 on April 21, 2026. According to Boundless Bio, the presentation is part of the Late‑Breaking Research: Experimental and Molecular Therapeutics 3 session.

Which cancer subtypes is the KOMODO‑1 trial (BOLD) focused on enrolling?

KOMODO‑1 is focused on advanced or metastatic ER+/HER2‑ and TNBC‑LAR breast cancers. According to Boundless Bio, those subtypes are specified for the first‑in‑human BBI‑940 study (NCT07408089).